01—Abstract
Summary
Summary of the 8-K filed June 4, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated filed a Regulation FD disclosure announcing a commercial webinar on June 4, 2024 at 8:00 a.m.
Eastern Time to discuss the market outlook for its three most advanced programs: ARIKAYCE (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP). The attached slide presentation, Exhibit 99.1, is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act. The presentation frames the three programs as having positive clinical data in hand.
It cites peak sales potential of more than $1 billiona for ARIKAYCE, more than $2 billion for TPIP, and more than $5 billion for brensocatib. It describes ARIKAYCE as currently approved for refractory MAC NTM, with an sNDA submission for MAC lung disease planned. It presents brensocatib as potentially a new standard of care in bronchiectasis, based on the ASPEN study, and TPIP as a once-daily inhaled prostanoid being developed for PH-ILD and PAH.
The presentation notes that brensocatib and TPIP are investigational and have not been approved by the FDA or any regulatory authority. It also lists upcoming catalysts, including ENCORE enrollment completion, ARISE top-line results, a Phase 2 HS initiation, and additional TPIP Phase 2 and Phase 3 milestones, and it includes a forward-looking statements caveat.
02—Key points
Key Highlights
- Item 7.01 announces a commercial webinar on June 4, 2024 at 8:00 a.m. ET covering the market outlook for ARIKAYCE, brensocatib, and TPIP.
- The presentation cites peak sales potential of more than $5 billion for brensocatib, more than $2 billion for TPIP, and more than $1 billion for ARIKAYCE.
- Brensocatib is positioned as a potential new standard of care in bronchiectasis, based on the ASPEN study, with a launch in the U.S. planned pending regulatory approval.
- TPIP is described as a once-daily inhaled treatment for PH-ILD and PAH, with Phase 2 PH-ILD topline safety and tolerability data disclosed on May 6, 2024.
- ARIKAYCE is currently approved for refractory MAC NTM, and the company plans an sNDA submission for MAC lung disease.
- Upcoming pipeline catalysts listed include ENCORE enrollment completion, ARISE and ASPEN-related milestones, a Phase 2 HS initiation, and TPIP PH-ILD and PAH readouts and Phase 3 initiations.
- Investigational products brensocatib and TPIP have not been approved by the FDA or any regulatory authority.
03—Questions
Frequently Asked Questions
What is the purpose of this filing?
The filing announces a commercial webinar on June 4, 2024 at 8:00 a.m. ET to discuss the market outlook for ARIKAYCE, brensocatib, and TPIP. The slide presentation used for the call is attached as Exhibit 99.1 and is furnished under Regulation FD, so it is not deemed filed under Section 18 of the Exchange Act.
What peak sales potential does the company cite for its programs?
The presentation cites peak sales potential of more than $5 billion for brensocatib, more than $2 billion for TPIP, and more than $1 billion for ARIKAYCE, with the TPIP and brensocatib figures tied to the company's stated expectations if approved.
What is the regulatory status of these products?
ARIKAYCE is approved in the U.S. for refractory MAC NTM, and the company plans an sNDA submission for MAC lung disease. Brensocatib and TPIP are investigational and have not been approved for sale or found safe or effective by the FDA or any other regulatory authority.
What are the key upcoming catalysts?
The presentation lists ENCORE enrollment completion, ARISE and ASPEN-related milestones, a Phase 2 HS initiation for brensocatib, and TPIP PH-ILD and PAH top-line results and Phase 3 initiations. Timing for several items is indicated as 2H24 or 2025 and 2026 launch expectations.
04—Continue